XOMA (NASDAQ: XOMA) and SIGA Technologies (OTCMKTS:SIGA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.
Valuation and Earnings
This table compares XOMA and SIGA Technologies’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|XOMA||$5.56 million||51.74||-$53.53 million||($7.18)||-4.92|
|SIGA Technologies||$14.99 million||25.79||-$39.69 million||($0.53)||-9.25|
This table compares XOMA and SIGA Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
XOMA has a beta of 3.19, suggesting that its stock price is 219% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500.
This is a summary of recent recommendations and price targets for XOMA and SIGA Technologies, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
XOMA presently has a consensus target price of $35.50, suggesting a potential upside of 0.45%. Given XOMA’s higher possible upside, research analysts clearly believe XOMA is more favorable than SIGA Technologies.
Institutional & Insider Ownership
33.5% of XOMA shares are owned by institutional investors. Comparatively, 6.7% of SIGA Technologies shares are owned by institutional investors. 3.0% of XOMA shares are owned by company insiders. Comparatively, 4.7% of SIGA Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
XOMA beats SIGA Technologies on 8 of the 13 factors compared between the two stocks.
XOMA Company Profile
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.
SIGA Technologies Company Profile
SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.
What are top analysts saying about XOMA? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for XOMA and related companies.